These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12478231)

  • 1. Stent design: implications for restenosis.
    McLean DR; Eiger NL
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S16-22. PubMed ID: 12478231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of stent design and coatings on restenosis and thrombosis.
    Hara H; Nakamura M; Palmaz JC; Schwartz RS
    Adv Drug Deliv Rev; 2006 Jun; 58(3):377-86. PubMed ID: 16650911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A stent is not just a stent: Stent construction and design do matter in its clinical performance.
    Lau KW; Johan A; Sigwart U; Hung JS
    Singapore Med J; 2004 Jul; 45(7):305-11; quiz 312. PubMed ID: 15221045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-eluting stents: role of stent design, delivery vehicle, and drug selection.
    Rodgers CD
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S10-5. PubMed ID: 12478230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective and efficient strategies for coronary revascularization in the drug-eluting stent era.
    Lepor NE; Madyoon H; Kereiakes D
    Rev Cardiovasc Med; 2002; 3 Suppl 5():S38-50. PubMed ID: 12478234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis.
    Vaina S; Ong AT; Serruys PW
    Minerva Cardioangiol; 2005 Oct; 53(5):341-60. PubMed ID: 16179880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary small-vessel stenting in the era of drug elution.
    Kereiakes DJ
    Rev Cardiovasc Med; 2004; 5 Suppl 2():S34-45. PubMed ID: 15184832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of stent design on clinical outcome after coronary stent implantation.
    Minim Invasive Ther Allied Technol; 2002 Jul; 11(4):203-9. PubMed ID: 16754071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: a prospective single-center registry in high-risk patients.
    Miglionico M; Patti G; D'Ambrosio A; Di Sciascio G
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):600-4. PubMed ID: 18360849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact of stent construction and design in percutaneous coronary intervention.
    Lau KW; Mak KH; Hung JS; Sigwart U
    Am Heart J; 2004 May; 147(5):764-73. PubMed ID: 15131529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of physical stent parameters upon restenosis.
    Morton AC; Crossman D; Gunn J
    Pathol Biol (Paris); 2004 May; 52(4):196-205. PubMed ID: 15145132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering aspects of stents design and their translation into clinical practice.
    Sangiorgi G; Melzi G; Agostoni P; Cola C; Clementi F; Romitelli P; Virmani R; Colombo A
    Ann Ist Super Sanita; 2007; 43(1):89-100. PubMed ID: 17536159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early experiences and clinical implications of drug-eluting stents: part 1.
    Chong PH; Cheng JW
    Ann Pharmacother; 2004 Apr; 38(4):661-9. PubMed ID: 14766994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.